4 minute read
Systemic sclerosis – a team approach
By Dr Janet Roddy, Rheumatologist, Shenton Park
Systemic sclerosis, (scleroderma) is a multi-system, heterogeneous condition. The clinical manifestations are a result of vascular system and fibroblast pathology. Most existing therapies are vasoactive or immunomodulatory. There are recognised associations between anti-centromere antibodies (ACA) and limited disease, anti-Scl-70 (anti-topo 1) with diffuse disease plus interstitial lung disease, anti-RNA polymerase III (RNAPIII) with diffuse disease plus renal cell crisis. Anti-PM/ Scl is associated with myositis/ scleroderma overlap. Correlations, such as the increased cancer risk seen in anti-RNA PMIII positive patients may be helpful clinically. Raynaud’s disease present in up to 90% of scleroderma patients, Key messages
Scleroderma is a heterogeneous disease. Careful monitoring and early treatment may prevent organ damage resulting in reduced morbidity and mortality. Therapy is geared to the organ involved with early immunosuppression in rapidly progressive diffuse disease.
is often refractory to Nifedipine and may be complicated by digital ulcers. Therapy with PDE5 inhibitors (sildenafil or tadalafil) and intravenous iloprost is often required. Bosentan, an endothelial receptor antagonist (ERA), may prevent recurrence of severe digital ulcers. Very few patients with isolated Raynaud’s develop scleroderma, but look for finger pulp pitting, abnormal nailfold capillaries or scleroderma antibodies.
Skin thickening, the hallmark of systemic sclerosis, begins distally often with puffy fingers and progresses proximally. Skin thickening reaching above the elbows and knees defines diffuse disease. These patients are at risk of internal organ involvement especially during the first three to five years. Pulmonary arterial hypertension may occur at any time, often in patients with limited scleroderma.
Home blood pressure monitoring may detect an early scleroderma renal crisis. Rapid introduction of ACE inhibitor therapy markedly improves outcome in this medical emergency.
Has your patient been injured at work or in a motor vehicle accident ?
Guardian Exercise Rehabilitation has 20 years’ experience in rehabilitation interventions.
Guardian Exercise Rehabilitation’s allied health clinicians provide treatment and prescription of therapeutic exercise-based programs for individuals afflicted with injury or illness, principally under a compensable-injury policy.
Experienced team of mobile Physiotherapists and Exercise Physiologists Industry leaders in clinical exercise interventions Outcomes focused with self-efficacy for clients Video consultations for remote patients throughout WA
Our clinicians consult clients across a broad spectrum of injuries and illnesses, with significant experience in both musculoskeletal injuries and mental illnesses. We consult clients throughout their recovery journey, from early intervention through to chronicity management. We adopt a biopsychosocial approach with emphasis on collaboration, education and empowerment. Our programs optimise function and healthy re-engagement in work, as well as everyday and recreational activities.
Referring to Guardian Exercise Rehabilitation will ensure your patient receives the most appropriate treatment required for the stage and complexity of their injury or condition. E-Refer now at guardianexercise.com.au
CURRENT APPROACH
ASIG STANDARD
TTE Primary Screening Tool SSc Patients
TTE & PFTs
Repeat in 12 months
Screen Positive sPAP>40mmHg or DLCO<50%* Screen Negative sPAP<40mmHg or DLCO>50%*
Right Heart Catheterisation
Low Probability of PAH
PAH No PAH
Figure 1- Australia Scleroderma Interest Group (ASIG) current approach for screening for Pulmonary arterial hypertension.
Pulmonary arterial hypertension (PAH) and interstitial lung disease accounts for most disease related mortality in scleroderma. The current approach for PAH screening is shown in figure 1. Treatment of PAH with ERAs alone or in combination with other therapies has reduced mortality. Immunosuppressive agents (e.g. Methotrexate, mycophenolate, cyclophosphamide and rituximab) are used to treat early progressive disease depending on organ involvement, severity and progression. Three randomised controlled trials found improved survival in select patients receiving autologous stem cell transplant compared to cyclophosphamide. Transplantrelated mortality is significant, so patient selection and centre experience is crucial if considering this option. The entire gastrointestinal tract may be involved in scleroderma.
Oesophageal reflux disease often requires high-dose proton pump inhibitor, in combination with H2 receptor antagonists. Small intestinal bacterial overgrowth (SIBO) may respond to an empirical course of rotating antibiotics. Rectal sphincter incontinence is common. Endoscopy or colonoscopy is often required, especially in patients not responding to therapy. Steroids may be necessary in some patients. However, be aware of the increased risk of renal cell crisis associated with prednisolone.
References available on request Author competing interests – nil
“When Annie lost her hearing, she began to lose her connection with Jack, too.
I just had to do something. “ Nezha Delorme, Amana Living Client Services Manager
“Annie had a stroke and lost her hearing. It became so hard for her to communicate with her friends and family, and it was especially hard on her husband, Jack, who loves her dearly and is her prime carer. During my training I’d learned how relationships can become strained as physical or communication difficulties arise. So, with the help of our IT team, we created a solution. We got an iPad for Annie and showed them how to use dictation software that converted Jack’s spoken words into text. It brought so much happiness back into their lives. And into mine.”
Professionally trained. Naturally kind.
1300 26 26 26 | amanaliving.com.au
